MAP2K7 and small cell lung carcinoma: Given that the CP-induced ERK activation might underlie the mechanism of SCLC cell survival and drug resistance during CP therapy, we investigated the effects of combining CP with U0126, a specific MEK/ERK inhibitor to inhibit the downstream ERK activation, on H446 cell line.